Baseline Prostate Volume and the Magnitude and Durability of the Volumetric Response After Prostatic Artery Embolization: A Retrospective Ultrasound-Based Time-to-Event Analysis

Background/Objectives: Whether the magnitude and durability of prostate volume reduction after prostatic artery embolization (PAE) depend on baseline gland size is unclear. Methods: Retrospective single-operator study at two institutions (2015–2024): 164 of 177 consecutive men treated by PAE for benign prostatic hyperplasia with evaluable transrectal ultrasound volumetry were stratified as small (30–65 mL, n = 53), medium (>65–100 mL, n = 70) or large (>100 mL, n = 41); median follow-up was 12.8 months. The primary endpoint was relative volume reduction at nadir. Durability was analysed in a 6-month landmark cohort of early responders (n = 87), with regrowth to ≥80% of baseline as an interval-censored event (Turnbull estimator; Cox regression on midpoint-imputed event times). Results: Median reduction at nadir was 41.7%, 40.1% and 39.1% in small, medium and large glands (p = 0.39); 10 patients (6.1%) never fell below 80% of baseline. Regrowth occurred in 27 of 87 landmark patients; the probability of sustained reduction 24 months after the landmark was 0.76 (95% confidence interval [CI] 0.61–0.88). Baseline volume was not significantly associated with durability (hazard ratio 0.97 per 10 mL, 95% CI 0.86–1.10), consistently across sensitivity analyses and after adjustment for 5-alpha-reductase inhibitor pretreatment, which was more than twice as common in large glands; in an exploratory analysis, deeper reduction by the landmark was associated with longer durability. Conclusions: No association between baseline volume and the magnitude or durability of the volumetric response was detected, but the confidence intervals are wide and do not exclude a clinically relevant effect. The durability estimates are conditional on an early volumetric response and continued follow-up and should not be generalised to the entire treated population; residual confounding by medical therapy cannot be excluded, and the findings concern prostate volume, not clinical efficacy.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2026-11-17
DOI
https://doi.org/10.3390/diagnostics16223838
Primary Topic
Urinary Bladder and Prostate Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Baseline Prostate Volume and the Magnitude and Durability of the Volumetric Response After Prostatic Artery Embolization: A Retrospective Ultrasound-Based Time-to-Event Analysis

Florian Wolf, Markus Margreiter, Michael Weber, Francesco Siciliano et al.
1 links
Diagnostics
Urinary Bladder and Prostate Research
article

Baseline Prostate Volume and the Magnitude and Durability of the Volumetric Response After Prostatic Artery Embolization: A Retrospective Ultrasound-Based Time-to-Event Analysis

Florian Wolf, Markus Margreiter, Michael Weber, Francesco Siciliano, Raoul Varga, Felix R. M. Koenig
article en

Abstract

Background/Objectives: Whether the magnitude and durability of prostate volume reduction after prostatic artery embolization (PAE) depend on baseline gland size is unclear. Methods: Retrospective single-operator study at two institutions (2015–2024): 164 of 177 consecutive men treated by PAE for benign prostatic hyperplasia with evaluable transrectal ultrasound volumetry were stratified as small (30–65 mL, n = 53), medium (>65–100 mL, n = 70) or large (>100 mL, n = 41); median follow-up was 12.8 months. The primary endpoint was relative volume reduction at nadir. Durability was analysed in a 6-month landmark cohort of early responders (n = 87), with regrowth to ≥80% of baseline as an interval-censored event (Turnbull estimator; Cox regression on midpoint-imputed event times). Results: Median reduction at nadir was 41.7%, 40.1% and 39.1% in small, medium and large glands (p = 0.39); 10 patients (6.1%) never fell below 80% of baseline. Regrowth occurred in 27 of 87 landmark patients; the probability of sustained reduction 24 months after the landmark was 0.76 (95% confidence interval [CI] 0.61–0.88). Baseline volume was not significantly associated with durability (hazard ratio 0.97 per 10 mL, 95% CI 0.86–1.10), consistently across sensitivity analyses and after adjustment for 5-alpha-reductase inhibitor pretreatment, which was more than twice as common in large glands; in an exploratory analysis, deeper reduction by the landmark was associated with longer durability. Conclusions: No association between baseline volume and the magnitude or durability of the volumetric response was detected, but the confidence intervals are wide and do not exclude a clinically relevant effect. The durability estimates are conditional on an early volumetric response and continued follow-up and should not be generalised to the entire treated population; residual confounding by medical therapy cannot be excluded, and the findings concern prostate volume, not clinical efficacy.

DiagnosticsVol. 16(22)
Rudolfinerhaus Hospital (AT), European Institute of Oncology (IT), Medical University of Vienna (AT)
Good health and well-being
Urinary Bladder and Prostate Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon